Evidence map›Paper›PMID 40042740›Full record

ReviewCurrent treatment options in oncology2025

Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma.

Fatemeh Karimi, Mojtaba Aghaei, Najmaldin Saki

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fatemeh KarimiAhvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID http://orcid.org/0009-0003-1692-3512
Mojtaba AghaeiAhvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID http://orcid.org/0000-0002-6382-6657
Najmaldin SakiThalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. najmaldinSaki@gmail.com.ORCID http://orcid.org/0000-0001-8494-5594

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementMultiple myeloma (MM) is classified as a lymphoproliferative disorder that remains an incurable malignancy despite improved patient survival with new drug therapies. Polymorphisms are essential in determining the effectiveness and outcome of treatments in MM. Despite significant advances, there needs to be more understanding of the underlying biological mechanisms that determine treatment outcomes. studies show that investigating gene polymorphisms involved in drug metabolism, DNA repair, inflammation, and apoptosis pathways can predict the effectiveness of treatment in MM patients. Therefore, these findings emphasize the potential of genetic profiling for predicting treatment outcomes and tailoring treatments to individual genetic profiles, which increases the efficiency and reduces the toxicity of MM treatments.

Indexed as

Immunomodulating AgentsMultiple MyelomaPolymorphism, GeneticProteasome InhibitorsBiomarkers, TumorHumansTreatment OutcomeBiomarkers, TumorImmunomodulating AgentsProteasome InhibitorsBiomarkersGenetic markersMultiple MyelomaPersonalized therapyPolymorphismsTreatment outcomes

Identifiers

PMID40042740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.